Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Robinson

Farnier

Krempf

. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–1499.

Sanofi US, Regeneron Pharmaceuticals. Praluent® (alirocumab) injection: important safety information. 2016. https://www.praluenthcp.com. Accessed February, 2016.

Ferri

Tibolla

Pirillo

. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012;220(2):381–386.

Feingold

Moser

Shigenaga

. Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun. 2008;374(2):341–344.

Van Poelgeest

Swart

Betjes

. Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis. 2013;62(4):796–800.

Praluent (Alirocumab)-Induced Renal Injury

Abstract

Get full access to this article

References